MedTrace Logo

Paracetamol as Antipyretic and Analgesic Medication

NCT01070732 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2010-02-18

No results posted yet for this study

Summary

The present study is aiming to unravel the clinical efficacy of intravenously administered paracetamol as antipyretic and analgesic medication in various medical conditions.

Conditions

Interventions

DRUG

Paracetamol

All patients will receive one single dose of 1000mg paracetamol. If considered mandatory by the attending physician, similar doses may be administered latter for a maximum period of five days. The maximum allowed daily dose is 3000mg. If the attending physician believes that after the administration of at least of three doses the desired analgesic or antipyretic effect is not achieved, he may administer any other compound in his will.

Sponsors & Collaborators

  • University of Athens

    lead OTHER

Principal Investigators

  • Evangelos J Giamarellos-Bourboulis, MD, PhD · University of Athens, Medical School

  • Helen Giamarellou, MD, PhD · ATTIKON University Hospital of Athens

  • George Koratzanis, MD, PhD · Sismanogelion General Hospital, Athens

  • Konstantinos Atmatzidis, MD, PhD · G.Gennimatas General Hospital of Thessaloniki

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01070732 on ClinicalTrials.gov